Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gossamer Bio Inc.

2.34
+0.17007.83%
Post-market: 2.30-0.0398-1.70%19:40 EDT
Volume:4.90M
Turnover:11.05M
Market Cap:532.07M
PE:-3.82
High:2.35
Open:2.17
Low:2.15
Close:2.17
52wk High:2.35
52wk Low:0.6617
Shares:227.38M
Float Shares:183.82M
Volume Ratio:2.43
T/O Rate:2.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6118
EPS(LYR):-0.2499
ROE:-783.37%
ROA:-29.63%
PB:-11.54
PE(LYR):-9.36

Loading ...

Director Sandra Milligan Reports Acquisition of Gossamer Bio Inc. Common Shares

Reuters
·
Aug 21

Gossamer Bio Inc. Announces New Stock Option Grants for Employees Under 2023 Inducement Plan

Reuters
·
Aug 08

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Aug 08

Leerink Partners Sticks to Its Buy Rating for Gossamer Bio (GOSS)

TIPRANKS
·
Aug 07

Gossamer Bio Is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 07

BRIEF-Gossamer Bio Q2 EPS USD -0.17

Reuters
·
Aug 06

Gossamer Bio Reports Q2 2025 Net Loss of $38.3M vs. $49.2M Net Income in 2024; Revenue Drops to $11.5M from $95.8M Due to Prior Year One-Time License Sale

Reuters
·
Aug 06

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 06

Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target

MT Newswires Live
·
Jul 14

Gossamer Bio Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 26

Gossamer Bio Completes Enrollment in Phase 3 PROSERA Study for PAH Treatment, Topline Results Expected February 2026

Reuters
·
Jun 16

Gossamer Bio Inc. Enters Global Collaboration Agreement with Chiesi Group for Development of Seralutinib

Reuters
·
Jun 16

BRIEF-Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule

Reuters
·
Jun 07

Gossamer Bio Is Maintained at Buy by Goldman Sachs

Dow Jones
·
May 17

Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush

Dow Jones
·
May 16

Piper Sandler Remains a Buy on Gossamer Bio (GOSS)

TIPRANKS
·
May 16

Gossamer Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Gossamer Bio Q1 EPS $(0.16) Beats $(0.18) Estimate, Sales $9.89M Beat $4.07M Estimate

Benzinga
·
May 16

BRIEF-Gossamer Bio Q1 EPS USD -0.16

Reuters
·
May 16

Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
May 13